Thalassemia-associated Osteoporosis: a Systematic Review on Treatment and Brief Overview of the Disease

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2016 Aug 10

PMID 27503175

Citations 33

Authors

A D Dede

G Trovas

E Chronopoulos

I K Triantafyllopoulos

I Dontas

N Papaioannou

S Tournis

Affiliations

Soon will be listed here.

Abstract

Thalassemia-associated osteoporosis constitutes a major complication in patients with thalassemia. This review presents the existing studies on the treatment of thalassemia-associated osteoporosis and discusses the management of this debilitating complication. A brief presentation of the disease characteristics and pathogenetic mechanisms is also provided. The life expectancy of patients with thalassemia has increased markedly in recent years resulting in the aging of the population and the emergence of new comorbidities. The majority of patients with thalassemia have low bone mineral density and experience lifelong fracture rates as high as 71 %. The pathogenesis of thalassemia-associated osteoporosis (TAO) is multifactorial with anemia and iron overload playing crucial role in its development. Data concerning the prevention and treatment of TAO are extremely limited. We performed a literature research in Pubmed and Scopus to identify interventional studies evaluating the effects of various agents on TAO. Seventeen studies were retrieved. We present the results of these studies as well as a brief overview of TAO including presentation, pathogenesis, and management. Most of the studies identified are of poor quality, are not randomized controlled, and include small number of participants. There are no data concerning effects on fracture rates. Bisphosphonates are the most widely studied agents and among them zoledronic acid is the most well studied. Hormone replacement treatment (HRT) shows beneficial but small effects. Denosumab and strontium ranelate have each been evaluated in only a single study, while there are no data about the effects of anabolic agents. Given the increased life expectancy and the increase in fracture rates with age, more data about the management of TAO are warranted. Moreover, due to the need for lifelong management starting at young age, careful treatment plans which may include sequential treatment may often be required. However, currently, there are no relevant data available.

Citing Articles

Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.

Ambrosio M, Cattaneo C, Gagliardi I, Carnevale A, Zatelli M J Endocrinol Invest. 2025; .

PMID: 39760968 DOI: 10.1007/s40618-024-02503-2.

Bone and Joint Involvement in Beta Thalassemic Patients: A Cross-sectional Study.

Khosla N, Nayyar A, Selhi A, Jain D, Kakkar S, Selhi H Indian J Orthop. 2024; 59(1):69-76.

PMID: 39735876 PMC: 11680515. DOI: 10.1007/s43465-024-01225-0.

Decoding ferroptosis: transforming orthopedic disease management.

Huo G, Lin Y, Liu L, He Y, Qu Y, Liu Y Front Pharmacol. 2024; 15:1509172.

PMID: 39712490 PMC: 11659002. DOI: 10.3389/fphar.2024.1509172.

Hypoparathyroidism in adults with iron overload diseases (IOD): evidence of a subclinical phenotype.

De Vincentis S, Evangelisti S, Rossi B, Decaroli M, Locaso M, Ansaloni A Endocrine. 2024; 87(3):1257-1266.

PMID: 39630327 DOI: 10.1007/s12020-024-04124-4.

Depletion of macrophages and osteoclast precursors mitigates iron overload-mediated bone loss.

Passin V, Ledesma-Colunga M, Altamura S, Muckenthaler M, Baschant U, Hofbauer L IUBMB Life. 2024; 77(1):e2928.

PMID: 39555707 PMC: 11611226. DOI: 10.1002/iub.2928.

References

Baldini M, Ulivieri F, Forti S, Serafino S, Seghezzi S, Marcon A . Spine bone texture assessed by trabecular bone score (TBS) to evaluate bone health in thalassemia major. Calcif Tissue Int. 2014; 95(6):540-6. DOI: 10.1007/s00223-014-9919-7. View

Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S . Pain over time and its effects on life in thalassemia. Am J Hematol. 2013; 88(11):939-43. PMC: 3872488. DOI: 10.1002/ajh.23565. View

Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A . Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002; 13(8):644-9. DOI: 10.1007/s001980200087. View

Bordat C, Constans A, BOUET O, Blanc I, Trubert C, Girot R . Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging. Calcif Tissue Int. 1993; 53(1):29-37. DOI: 10.1007/BF01352012. View

Yang Q, Jian J, Abramson S, Huang X . Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res. 2011; 26(6):1188-96. DOI: 10.1002/jbmr.337. View

Michelson J, Cohen A . Incidence and treatment of fractures in thalassemia. J Orthop Trauma. 1988; 2(1):29-32. DOI: 10.1097/00005131-198802000-00007. View

Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N . Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol. 2013; 35(3):212-7. DOI: 10.1097/MPH.0b013e3182841574. View

Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B . The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 2000; 96(10):3624-9. View

Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T . Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol. 2013; 160(5):680-7. DOI: 10.1111/bjh.12177. View

10.

Dines D, Canale V, Arnold W . Fractures in thalassemia. J Bone Joint Surg Am. 1976; 58(5):662-6. View

11.

Fung E . Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci. 2010; 1202:188-96. DOI: 10.1111/j.1749-6632.2010.05578.x. View

12.

Angelopoulos N, Katounda E, Rombopoulos G, Goula A, Kaltzidou V, Kaltsas D . Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy x-ray absorptiometry and quantitative computed tomography: a comparison study. J Pediatr Hematol Oncol. 2006; 28(2):73-8. DOI: 10.1097/01.mph.0000199587.76055.21. View

13.

Waung J, Bassett J, Williams G . Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab. 2011; 23(4):155-62. DOI: 10.1016/j.tem.2011.11.002. View

14.

Lu H, Lian L, Shi D, Zhao H, Dai Y . Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells. Mol Med Rep. 2014; 11(1):143-50. PMC: 4237087. DOI: 10.3892/mmr.2014.2769. View

15.

Vogiatzi M, Macklin E, Fung E, Vichinsky E, Olivieri N, Kwiatkowski J . Prevalence of fractures among the Thalassemia syndromes in North America. Bone. 2005; 38(4):571-5. PMC: 4594870. DOI: 10.1016/j.bone.2005.10.001. View

16.

Polyzos S, Anastasilakis A, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E . Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2011; 23(3):1171-6. DOI: 10.1007/s00198-010-1525-6. View

17.

Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C . Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006; 91(9):1193-202. View

18.

Olivieri N, Koren G, Harris J, Khattak S, Freedman M, Templeton D . Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992; 14(1):48-56. DOI: 10.1097/00043426-199221000-00007. View

19.

Eghbali-Fatourechi G . Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord. 2015; 13(1):109. PMC: 4279811. DOI: 10.1186/s40200-014-0109-y. View

20.

Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A . Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 2009; 94(5):725-8. PMC: 2675686. DOI: 10.3324/haema-tol.2008.000893. View